After a heart attack, most people would do anything to prevent another one, but adherence to prevention strategies often declines over time. This is a critical issue, especially given the high risk of another event after an acute coronary syndrome (ACS). Today, we delve into the 2025 Australian Guideline on Acute Coronary Syndromes, focusing on secondary prevention—a topic that's both crucial and often overlooked. But here's where it gets controversial: despite the high stakes, many patients stop taking their medications, leading to preventable events. And this is the part most people miss: the dramatic decline in medication adherence from 90% at discharge to just over 65% at two years. So, what can we do about it? We're joined by Professor David Brieger, Head of Cardiology at Concord Hospital and a professor at the University of Sydney, who co-chaired the guideline writing group. Together, we'll explore the recommendations and strategies to improve patient uptake and maintenance of these life-saving measures.
Why Secondary Prevention Matters
Many events following an ACS occur in the months after the initial event, and these can be effectively prevented through secondary prevention therapies. However, patients often view themselves as cured after their event and stop taking medications. This non-adherence has severe consequences, leading to numerous preventable events. Therefore, prioritizing post-discharge education and management is essential to ensure patients continue their medications and other strategies.
Who’s Responsible for Secondary Prevention?
While the guideline primarily targets medical professionals, secondary prevention increasingly falls on nursing staff, allied health professionals, and those offering rehabilitation services. Ultimately, cardiologists initiate prescriptions in the hospital, and GPs provide ongoing oversight and engagement post-discharge.
Non-Pharmacological Strategies
A significant focus of secondary prevention is on non-pharmacological strategies, which involve the entire multidisciplinary team. Key recommendations include:
1. Referring all patients to a multidisciplinary, exercise-based rehab program after an ACS.
2. Providing education on behavioral changes like healthy eating, regular activity, smoking cessation, limiting alcohol, and mental health care.
3. Optimizing medication adherence through alerts, reminders, and fixed-dose combinations.
4. Screening for depression and other mental health conditions, which are major drivers of non-adherence.
5. Ensuring patients know what to do if symptoms recur, including having a chest pain management plan.
Pharmacological Options
Antiplatelet medications are well-established in secondary prevention, with the new guidelines emphasizing tailored durations based on patient risk profiles. For instance, dual antiplatelet therapy (DAPT) duration has shifted from the traditional 12 months to 6-12 months, depending on bleeding and ischemic risks. Clopidogrel is now preferred over aspirin for long-term single-agent therapy due to its effectiveness and safety.
Controversial Interpretations and Counterpoints
One controversial area is the use of colchicine for its anti-inflammatory effects post-ACS. While some trials show benefit, recent data question its efficacy, leading to a weak recommendation in the guideline. This highlights the ongoing debate and need for further research.
Thought-Provoking Questions
How can we better address medication non-adherence in ACS patients? Should we prioritize early aggressive lipid-lowering therapy, and what role do GLP-1s and SGLT2s play in secondary prevention? These questions invite discussion and differing opinions, encouraging clinicians to voice their perspectives.
Final Thoughts
As we wrap up, remember that secondary prevention is not just about medications—it’s about a holistic approach involving non-pharmacological strategies, patient education, and multidisciplinary care. Let’s keep the conversation going and work together to improve outcomes for ACS patients. What are your thoughts on these recommendations? Share your views in the comments below!
